Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
Eligibility criteria
Qualifiers
HBV SAg positive and/or HBV NAT+ donor
Disqualifiers
HIV positive
HTLV 1/2 positive;
Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc).
Recipients eligible and listed for lung transplant
Trial design
Treatments tested in this trial
- Entecavir
- HBIG
- EVLP UV Light Treatment
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1University Health Network, Toronto General HospitalM5G 2C4, TorontoOntario, Canada
Sponsors and collaborators
University Health Network, Toronto
Lead sponsor
Source ClinicalTrials.gov